5465 Legacy Dr. Suite 550 - Plano, TX 75024
(214) 919-4982

Hereditary Cancer

unknown-4This non-invasive assessment helps the patient and clinician determine the level of risk for some of the most common solid tumor cancers including Breast, Ovarian, Endometrial, Pancreatic, Prostate, Skin, Gastric and Colorectal Cancers. Patients who test “positive” for certain mutations have a significantly higher risk of cancer than the general population. Assists physicians in recommending solutions for healthy lifestyle management, medications and / or surgical procedures. The information enables patients to put a preventative plan in place to reduce their risk of getting cancer.

This assessment evaluates an individual’s genetic risk of developing primary inherited cancers over their lifetime. Equipped with the results of this test, alongside medical and family history, a strategy can be created to reduce the risk of developing one of these many types of cancers. Not everyone with a cancer-related mutation will develop cancer.

  • Determines if a patient has genetic mutations that correlate with increased risk of several types of primary inherited cancers
  • Provides information to delay or avert the development of certain cancers
  • Assists physicians in recommending solutions for healthy lifestyle management, medications and / or surgical procedures

What is a Hereditary Cancer Assessment?

A genetic test that evaluates an individual’s genetic risk of developing 8 primary inherited cancers over their lifetime. Equipped with the results of up to a 94-gene panel, alongside medical and family history, a strategy can be created to reduce the risk of developing one of these many types of cancers.

It is important to remember that not everyone with a cancer-related variation will develop cancer and not everyone with personal or a strong family history of cancer will necessarily have variants that are known to be disease causing. Also, a negative result does not mean a patient will not get cancer in their lifetime.

Benefits of Testing

  • Evaluate a patient’s genetic risk of developing primary inherited cancers
  • Allows a patient to establish their healthcare plan with their clinician that will help potentially reduce their risk
  • Potential to improve outcomes and reduces medical costs through earlier diagnosis and treatment of cancer if it develops

Who Should be Tested?

  • Patients with a personal history of cancer
  • Patients with a family history of cancer
  • Patients with a family history of early onset of cancer
  • Patients with a family history of multiple types of cancer

The Facts

  • Cancer counts for every 1 in 4 DEATHS in the U.S. each year.
  • Medical expenditures for cancer in the year 2020 are projected to reach at least $158 BILLION, an increase of 27% over 2010.
  • In 2016, an estimated 1,685,210 people will be diagnosed with cancer in the United States, and an estimated 595,690 people will die of cancer
  • 6 BILLION NEW CASES will be diagnosed this year. (168,000 potentially hereditary)
  • 3 TO 35 PERCENT Estimates of the premature deaths that could have been avoided through screening, depending on a variety of assumptions.
  • Together, BRCA1 and BRACA2 mutations account for about 20-25% of hereditary breast cancers and about 5-10% of all breast cancers
  • Each child of a parent who carries a mutation in one of these genes has a 50% chance (or 1 chance in 2) of inheriting the mutation

Have questions? Visit our FAQ Page

HAVE QUESTIONS ABOUT  HEREDITARY CANCER?